Literature DB >> 16876138

Metabotropic glutamate receptor antagonists: novel therapeutics for nicotine dependence and depression?

Athina Markou1.   

Abstract

Nicotine dependence is the primary motivational factor perpetuating the tobacco smoking habit that is one of the leading preventable causes of morbidity throughout the world. This Neuroscience Perspectives article summarizes and discusses recent evidence demonstrating the critical role of glutamate transmission in nicotine dependence and emerging data suggesting that compounds acting as antagonists at metabotropic glutamate receptors may be useful therapeutics to assist people in achieving and maintaining abstinence from tobacco smoking. Metabotropic glutamate 5 receptor antagonists may be useful in decreasing the reinforcing effects of nicotine, reducing motivation for nicotine and preventing relapse during protracted abstinence, whereas metabotropic glutamate 2/3 receptor antagonists may alleviate the depression observed during the early nicotine withdrawal phase. Metabotropic glutamate 2/3 receptor antagonists may also be therapeutics for non-drug-induced depressions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876138     DOI: 10.1016/j.biopsych.2006.03.053

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  26 in total

Review 1.  New medications for drug addiction hiding in glutamatergic neuroplasticity.

Authors:  P W Kalivas; N D Volkow
Journal:  Mol Psychiatry       Date:  2011-04-26       Impact factor: 15.992

Review 2.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

Review 3.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

4.  Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.

Authors:  Matthias E Liechti; Athina Markou
Journal:  Eur J Pharmacol       Date:  2006-10-17       Impact factor: 4.432

Review 5.  Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.

Authors:  Samuel A Barnes; Douglas J Sheffler; Svetlana Semenova; Nicholas D P Cosford; Anton Bespalov
Journal:  Biol Psychiatry       Date:  2018-03-09       Impact factor: 13.382

Review 6.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

7.  Physiological effects of cigarette smoking in the limbic system revealed by 3 tesla magnetic resonance spectroscopy.

Authors:  Angelika Mennecke; Andrea Gossler; Thilo Hammen; Arnd Dörfler; Andreas Stadlbauer; Julie Rösch; Johannes Kornhuber; Stefan Bleich; Marc Dölken; Norbert Thürauf
Journal:  J Neural Transm (Vienna)       Date:  2014-03-19       Impact factor: 3.575

Review 8.  Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction.

Authors:  Alan J Cross; Robert Anthenelli; Xia Li
Journal:  Biol Psychiatry       Date:  2017-11-21       Impact factor: 13.382

9.  Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.

Authors:  Douglas J Sheffler; Cody J Wenthur; Joshua A Bruner; Sheridan J S Carrington; Paige N Vinson; Kiran K Gogi; Anna L Blobaum; Ryan D Morrison; Mitchell Vamos; Nicholas D P Cosford; Shaun R Stauffer; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

Review 10.  Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.

Authors:  Matthias E Liechti; Athina Markou
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.